Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Plus Zanubrutinib in Newly Diagnosed and Previously Treated CLL/SLL
NCT07734038Phase 2Recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 cohorts). Primary endpoint: Rate of undetectable minimal residual disease at cycle 15. Started Oct 2026; status: recruiting.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT07734038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07734038.